1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48.
2023.PubMed/NCBI View Article : Google Scholar
|
2
|
Bahadoram S, Davoodi M, Hassanzadeh S,
Bahadoram M, Barahman M and Mafakher L: Renal cell carcinoma: An
overview of the epidemiology, diagnosis, and treatment. G Ital
Nefrol. 39:2022–vol3. 2022.PubMed/NCBI
|
3
|
Acosta PH, Panwar V, Jarmale V, Christie
A, Jasti J, Margulis V, Rakheja D, Cheville J, Leibovich BC, Parker
A, et al: Intratumoral resolution of driver gene mutation
heterogeneity in renal cancer using deep learning. Cancer Res.
82:2792–2806. 2022.PubMed/NCBI View Article : Google Scholar
|
4
|
Deligiannis D, Anastasiou I, Mitropoulos
D, Mitsos P and Theocharis S: Clinical importance of cannabinoid
type 1 receptor (CB1R) and cannabinoid type 2 receptor CB2R)
expression in renal cell carcinoma. Cureus.
16(e55121)2024.PubMed/NCBI View Article : Google Scholar
|
5
|
Singh N, Baby D, Rajguru JP, Patil PB,
Thakkannavar SS and Pujari VB: Inflammation and cancer. Ann Afr
Med. 18:121–126. 2019.PubMed/NCBI View Article : Google Scholar
|
6
|
Marelli G, Sica A, Vannucci L and Allavena
P: Inflammation as target in cancer therapy. Curr Opin Pharmacol.
35:57–65. 2017.PubMed/NCBI View Article : Google Scholar
|
7
|
Anfray C, Ummarino A, Andón FT and
Allavena P: Current strategies to target
tumor-associated-macrophages to improve anti-tumor immune
responses. Cells. 9(46)2019.PubMed/NCBI View Article : Google Scholar
|
8
|
Stober VP, Lim YP, Opal S, Zhuo L, Kimata
K and Garantziotis S: Inter-α-inhibitor ameliorates endothelial
inflammation in sepsis. Lung. 197:361–369. 2019.PubMed/NCBI View Article : Google Scholar
|
9
|
Hamm A, Veeck J, Bektas N, Wild PJ,
Hartmann A, Heindrichs U, Kristiansen G, Werbowetski-Ogilvie T,
Maestro RD, Knuechel R, et al: Frequent expression loss of
Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple
human solid tumors: A systematic expression analysis. BMC Cancer.
8(25)2008.PubMed/NCBI View Article : Google Scholar
|
10
|
Qian X, Bao ZM, Yao D and Shi Y: Lysine
demethylase 5C epigenetically reduces transcription of ITIH1 that
results in augmented progression of liver hepatocellular carcinoma.
Kaohsiung J Med Sci. 38:437–446. 2022.PubMed/NCBI View Article : Google Scholar
|
11
|
Chang QH, Mao T, Tao Y, Dong T, Tang XX,
Ge GH and Xu ZJ: Pan-cancer analysis identifies ITIH1 as a
novel prognostic indicator for hepatocellular carcinoma. Aging
(Albany NY). 13:11096–11119. 2021.PubMed/NCBI View Article : Google Scholar
|
12
|
Kopylov AT, Stepanov AA, Malsagova KA,
Soni D, Kushlinsky NE, Enikeev DV, Potoldykova NV, Listitsa AV and
Kaysheva AL: Revelation of proteomic indicators for colorectal
cancer in initial stages of development. Molecules.
25(619)2020.PubMed/NCBI View Article : Google Scholar
|
13
|
Vaghari-Tabari M, Ferns GA, Qujeq D,
Andevari AN, Sabahi Z and Moein S: Signaling, metabolism, and
cancer: An important relationship for therapeutic intervention. J
Cell Physiol. 236:5512–5532. 2021.PubMed/NCBI View Article : Google Scholar
|
14
|
Peng C, Ouyang Y, Lu N and Li N: The NF-κB
signaling pathway, the microbiota, and gastrointestinal
tumorigenesis: Recent advances. Front Immunol.
11(1387)2020.PubMed/NCBI View Article : Google Scholar
|
15
|
Liu W, Yan B, Yu H, Ren J, Peng M, Zhu L,
Wang Y, Jin X and Yi L: OTUD1 stabilizes PTEN to inhibit the
PI3K/AKT and TNF-alpha/NF-kappaB signaling pathways and sensitize
ccRCC to TKIs. Int J Biol Sci. 18:1401–1414. 2022.PubMed/NCBI View Article : Google Scholar
|
16
|
Yu H, Lin L, Zhang Z, Zhang H and Hu H:
Targeting NF-κB pathway for the therapy of diseases: Mechanism and
clinical study. Signal Transduct Target Ther. 5(209)2020.PubMed/NCBI View Article : Google Scholar
|
17
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658.
2017.PubMed/NCBI View Article : Google Scholar
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
19
|
Chen J and Chen ZJ: Regulation of NF-κB by
ubiquitination. Curr Opin Immunol. 25:4–12. 2013.PubMed/NCBI View Article : Google Scholar
|
20
|
Chowdhury N and Drake CG: Kidney cancer:
An overview of current therapeutic approaches. Urol Clin North Am.
47:419–431. 2020.PubMed/NCBI View Article : Google Scholar
|
21
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI View Article : Google Scholar
|
22
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
23
|
Ribatti D: A revisited concept: Contact
inhibition of growth. From cell biology to malignancy. Exp Cell
Res. 359:17–19. 2017.PubMed/NCBI View Article : Google Scholar
|
24
|
Niland S, Riscanevo AX and Eble JA: Matrix
metalloproteinases shape the tumor microenvironment in cancer
progression. Int J Mol Sci. 23(146)2021.PubMed/NCBI View Article : Google Scholar
|
25
|
Li X, Li Y, Lu W, Chen M, Ye W and Zhang
D: The tumor vessel targeting strategy: A double-edged sword in
tumor metastasis. Cells. 8(1602)2019.PubMed/NCBI View Article : Google Scholar
|
26
|
Shariati M and Meric-Bernstam F: Targeting
AKT for cancer therapy. Expert Opin Invesig Drugs. 28:977–988.
2019.PubMed/NCBI View Article : Google Scholar
|
27
|
Wang K, Chen Q, Shao Y, Yin S, Liu C, Liu
Y, Wang R, Wang T, Qiu Y and Yu H: Anticancer activities of TCM and
their active components against tumor metastasis. Biomed
Pharmacother. 133(111044)2021.PubMed/NCBI View Article : Google Scholar
|
28
|
Carneiro BA and EI-Deiry WS: Targeting
apoptosis in cancer therapy. Nat Rev Clin Oncol. 17:395–417.
2020.PubMed/NCBI View Article : Google Scholar
|
29
|
O'Dea E and Hoffmann A: NF-κB signaling.
Wiley Interdiscip Rev Syst Biol Med. 1:107–115. 2009.PubMed/NCBI View Article : Google Scholar
|
30
|
Yan YL, Bao G, Pei J, Cao Y, Zhang C, Zhao
P, Zhang Y and Damirin A: NF-κB and EGFR participate in
S1PR3-mediated human renal cell carcinomas progression. Biochim
Biophys Acta Mol Basis Dis. 1868(166401)2022.PubMed/NCBI View Article : Google Scholar
|
31
|
Akkoc Y, Dalci K, Karakas HE, Erbil-Bilir
S, Yalav O, Sakman G, Celik F, Arikan S, Zeybek U, Ergin M, et al:
Tumor-derived CTF1 (cardiotrophin 1) is a critical mediator of
stroma-assisted and autophagy-dependent breast cancer cell
migration, invasion and metastasis. Autophagy. 19:306–323.
2023.PubMed/NCBI View Article : Google Scholar
|
32
|
De Marco M, Del Papa N, Reppucci F, Iorio
V, Basile A, Falco A, Iaccarino R, Brongo S, De Caro F, Capunzo M,
et al: BAG3 induces α-SMA expression in human fibroblasts and its
over-expression correlates with poorer survival in fibrotic cancer
patients. J Cell Biochem. 123:91–101. 2022.PubMed/NCBI View Article : Google Scholar
|
33
|
Valcz G, Sipos F, Krenács T, Molnár J,
Patai AV, Leiszter K, Tóth K, Wichmann B, Molnár B and Tulassay Z:
Increase of α-SMA(+) and CK (+) cells as an early sign of
epithelial-mesenchymal transition during colorectal carcinogenesis.
Pathol Oncol Res. 18:371–376. 2012.PubMed/NCBI View Article : Google Scholar
|
34
|
Nitulescu GM, Van De Venter M, Nitulescu
G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Grădinaru D, Tsatsakis
A, Tsoukalas D, et al: The Akt pathway in oncology therapy and
beyond (Review). Int J Oncol. 53:2319–2331. 2018.PubMed/NCBI View Article : Google Scholar
|